Bivalirudin for treatment of aortic valve thrombosis after left ventricular assist device implantation

ASAIO J. 2013 Jul-Aug;59(4):448-9. doi: 10.1097/MAT.0b013e3182937a65.

Abstract

Ventricular assist devices are increasingly being used for mechanical support in patients with advanced heart failure. However, thromboembolism remains a leading cause of mortality in this population. We describe the successful treatment of native aortic valve thrombosis with bivalirudin in a patient with factor V Leiden mutation, who had undergone left ventricular assist device implantation, preventing the need for further surgical intervention.

Publication types

  • Case Reports

MeSH terms

  • Antithrombins / therapeutic use*
  • Aortic Valve
  • Bicuspid Aortic Valve Disease
  • Coronary Thrombosis / drug therapy*
  • Coronary Thrombosis / etiology
  • Female
  • Heart Defects, Congenital / drug therapy*
  • Heart Defects, Congenital / etiology
  • Heart Valve Diseases / drug therapy*
  • Heart Valve Diseases / etiology
  • Heart-Assist Devices / adverse effects*
  • Hirudins
  • Humans
  • Middle Aged
  • Peptide Fragments / therapeutic use*
  • Recombinant Proteins / therapeutic use

Substances

  • Antithrombins
  • Hirudins
  • Peptide Fragments
  • Recombinant Proteins
  • bivalirudin